Td Asset Management Inc Xencor Inc Transaction History

Td Asset Management Inc

  • $108 Billion
  • Q2 2025

A detailed history of Td Asset Management Inc transactions in Xencor Inc stock. As of the latest transaction made, Td Asset Management Inc holds 101,722 shares of XNCR stock, worth $1.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
101,722
Previous 101,722 -0.0%
Holding current value
$1.53 Million
Previous $1.08 Million 26.16%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 07, 2025
SELL
$10.64 - $24.13 $117,040 - $265,430
-11,000 Reduced 9.76%
101,722 $1.08 Million
Q4 2024

Feb 11, 2025
SELL
$19.43 - $26.84 $243,419 - $336,251
-12,528 Reduced 10.0%
112,722 $2.59 Million
Q3 2024

Nov 01, 2024
SELL
$15.7 - $21.65 $320,280 - $441,660
-20,400 Reduced 14.01%
125,250 $2.52 Million
Q2 2024

Aug 02, 2024
BUY
$18.21 - $24.5 $40,062 - $53,900
2,200 Added 1.53%
145,650 $2.76 Million
Q1 2024

May 08, 2024
BUY
$18.65 - $26.52 $376,730 - $535,704
20,200 Added 16.39%
143,450 $3.17 Million
Q4 2023

Feb 12, 2024
SELL
$16.53 - $21.42 $940,788 - $1.22 Million
-56,914 Reduced 31.59%
123,250 $2.62 Million
Q3 2023

Oct 27, 2023
BUY
$20.08 - $25.39 $1.32 Million - $1.67 Million
65,825 Added 57.57%
180,164 $3.63 Million
Q2 2023

Aug 09, 2023
SELL
$24.77 - $29.9 $304,844 - $367,979
-12,307 Reduced 9.72%
114,339 $2.86 Million
Q1 2023

May 10, 2023
BUY
$25.95 - $36.95 $277,665 - $395,365
10,700 Added 9.23%
126,646 $3.53 Million
Q4 2022

Feb 06, 2023
BUY
$24.79 - $30.86 $37,185 - $46,290
1,500 Added 1.31%
115,946 $3.02 Million
Q2 2022

Aug 04, 2022
SELL
$19.74 - $29.01 $209,717 - $308,202
-10,624 Reduced 8.49%
114,446 $3.13 Million
Q1 2022

May 10, 2022
SELL
$26.68 - $41.63 $477,358 - $744,843
-17,892 Reduced 12.52%
125,070 $3.34 Million
Q4 2021

Feb 10, 2022
BUY
$33.67 - $43.44 $1.02 Million - $1.32 Million
30,415 Added 27.02%
142,962 $5.74 Million
Q2 2021

Aug 11, 2021
SELL
$34.33 - $44.68 $177,005 - $230,370
-5,156 Reduced 4.38%
112,547 $3.46 Million
Q1 2021

May 14, 2021
BUY
$40.81 - $53.88 $455,480 - $601,354
11,161 Added 10.48%
117,703 $5.07 Million
Q4 2020

Feb 16, 2021
BUY
$36.63 - $47.63 $91,575 - $119,075
2,500 Added 2.4%
106,542 $4.65 Million
Q3 2020

Nov 10, 2020
BUY
$30.09 - $43.02 $404,951 - $578,963
13,458 Added 14.86%
104,042 $4.04 Million
Q2 2020

Aug 13, 2020
BUY
$27.76 - $33.42 $33,312 - $40,104
1,200 Added 1.34%
90,584 $2.93 Million
Q1 2020

May 15, 2020
SELL
$20.69 - $37.79 $82,760 - $151,160
-4,000 Reduced 4.28%
89,384 $2.67 Million
Q4 2019

Feb 11, 2020
SELL
$32.75 - $41.43 $383,175 - $484,731
-11,700 Reduced 11.13%
93,384 $3.21 Million
Q3 2019

Nov 07, 2019
SELL
$33.73 - $46.27 $279,959 - $384,041
-8,300 Reduced 7.32%
105,084 $3.54 Million
Q2 2019

Aug 01, 2019
SELL
$29.6 - $40.93 $246,242 - $340,496
-8,319 Reduced 6.84%
113,384 $4.64 Million
Q1 2019

May 08, 2019
SELL
$27.85 - $38.09 $367,620 - $502,788
-13,200 Reduced 9.78%
121,703 $3.78 Million
Q4 2018

Feb 01, 2019
SELL
$32.39 - $42.05 $59,629 - $77,414
-1,841 Reduced 1.35%
134,903 $4.88 Million
Q3 2018

Nov 01, 2018
BUY
$35.69 - $47.65 $578,178 - $771,930
16,200 Added 13.44%
136,744 $5.33 Million
Q2 2018

Jul 31, 2018
BUY
$28.41 - $42.41 $156,255 - $233,254
5,500 Added 4.78%
120,544 $4.46 Million
Q1 2018

May 11, 2018
BUY
$21.18 - $33.78 $301,243 - $480,452
14,223 Added 14.11%
115,044 $3.45 Million
Q4 2017

Feb 02, 2018
BUY
$19.29 - $24.83 $44,367 - $57,108
2,300 Added 2.33%
100,821 $2.21 Million
Q3 2017

Nov 09, 2017
BUY
$19.61 - $23.35 $1.93 Million - $2.3 Million
98,521
98,521 $2.26 Million

Others Institutions Holding XNCR

# of Institutions
207
Shares Held
81.9M
Call Options Held
0
Put Options Held
0
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $900M
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email